Compare · KAPA vs NVO
KAPA vs NVO
Side-by-side comparison of Kairos Pharma Ltd. (KAPA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KAPA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.96B, about 14343.4x KAPA ($12.8M).
- Over the past year, KAPA is down 26.7% and NVO is down 34.2% - KAPA leads by 7.5 points.
- NVO has been more active in the news (6 items in the past 4 weeks vs 1 for KAPA).
- NVO has more recent analyst coverage (25 ratings vs 0 for KAPA).
- Company
- Kairos Pharma Ltd.
- Novo Nordisk A/S
- Price
- $0.61+0.48%
- $41.27+0.22%
- Market cap
- $12.8M
- $183.96B
- 1M return
- +3.18%
- +13.19%
- 1Y return
- -26.70%
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NYSE
- IPO
- 2024
- News (4w)
- 1
- 6
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest KAPA
- Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation
- SEC Form 424B3 filed by Kairos Pharma Ltd.
- SEC Form 424B3 filed by Kairos Pharma Ltd.
- SEC Form 10-K filed by Kairos Pharma Ltd.
- Kairos Pharma Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics
- Kairos Pharma Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics
- SEC Form EFFECT filed by Kairos Pharma Ltd.
- DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S